BAM
MACK

Brave Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Brave Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,686
Closed -$36K – 161
2017
Q2 		$36K Hold
3,686
– – 0.02% 146
2017
Q1 		$89K Buy
3,686
+1,907
+107% +$47.7K 0.05% 146
2016
Q4 		$57K Sell
1,779
-128
-7% -$5.46K 0.04% 145
2016
Q3 		$95K Buy
1,907
+636
+50% +$26.4K 0.06% 180
2016
Q2 		$54K Hold
1,271
– – 0.04% 216
2016
Q1 		$84K Hold
1,271
– – 0.06% 184
2015
Q4 		$79K Buy
1,271
+254
+25% +$17.9K 0.05% 189
2015
Q3 		$68K Hold
1,017
– – 0.05% 191
2015
Q2 		$99K Sell
1,017
-127
-11% -$12.1K 0.07% 171
2015
Q1 		$107K Sell
1,144
-127
-10% -$10.8K 0.08% 163
2014
Q4 		$113K Sell
1,271
-508
-29% -$37K 0.08% 159
2014
Q3 		$123K Buy
1,779
+635
+56% +$33.9K 0.09% 154
2014
Q2 		$66K Buy
+1,144
New +$58.1K 0.05% 202

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brave Asset Management's MACK Position: Q3 2017 in Review

Brave Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,686 shares — an estimated $36K sold.

Brave Asset Management first reported a position in MACK in Q2 2014 and held it in 13 quarters. The position peaked at $123K in Q3 2014. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Brave Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Brave Asset Management sold 3,686 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $36K.
  • Brave Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 13 quarters.
  • Brave Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $123K in Q3 2014.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Brave Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.